Phase I-IV CRO Services: WuXiPRA

WuXiPRA Clinical Research delivers comprehensive clinical trial services from Phase I-IV and is the third largest Clinical Research Organization (CRO) in Greater China. By leveraging PRA Health Sciences’ (PRA) sophisticated global systems, SOPs and processes, WuXiPRA has the resources necessary to support clinical trials of any size and scope.

Our project teams have experience overcoming some of China’s toughest operational challenges, including regulatory and ethics committee submissions, site contract negotiation, drug and sample import/export processes and drug safety reporting.

WuXiPRA has more than 400 employees operating in 17 cities and five offices, including Shanghai, Beijing, Guangzhou, Wuhan and Hong Kong. We cover China’s major territories and have built a robust network of strategically located CRAs, who cultivate local relationships and target the most productive sites for recruitment and data quality.